Recent Comments

Comment RSS

Etanercept News and Research RSS Feed - Etanercept News and Research

Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.

Idera Pharmaceuticals announces financial results for the third quarter of 2009

5. November 2009 07:54
Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. [More]

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

29. October 2009 01:00
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. [More]

Cephalon, BDC sign option agreement

26. October 2009 09:15
Cephalon, Inc. and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , ,

RA patients who adhere to their prescription drug regimen have better outcome: Study

20. October 2009 04:15
Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia. [More]

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

19. October 2009 09:41
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting. [More]

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

7. October 2009 04:34
More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe. [More]

Reportlinker's medical review criteria guidelines for managing care

30. September 2009 08:03
Reportlinker Adds Medical Review Criteria Guidelines for Managing Care (8th ed. - 2009) [More]

Posted in: Healthcare News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Preclinical data on Protalix Biotherapeutics' antiTNF released

23. September 2009 03:56
Protalix Biotherapeutics, Inc., reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel). Produced using the Company’s proprietary ProCellEx technology, pr-antiTNF is a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody IgG1 domain. Pr-antiTNF has an identical amino acid sequence to Enbrel. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , ,

Comprehensive and practical overview of psoriasis

22. September 2009 06:00
Treatments for psoriasis often present a therapeutic challenge to physicians because, besides affecting the skin, psoriasis may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases). [More]

Event to address rheumatoid arthritis

22. September 2009 05:45
26 men and women with RA from across europe honoured as they share their inspirational stories. Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA). [More]

New report on the psoriasis market offered by Research and Markets

4. September 2009 05:15
Research and Markets (http://www.researchandmarkets.com/research/b8d445/commercial_insight) has announced the addition of the "Commercial Insight: Psoriasis - Intellectual property drives growth" report to their offering. [More]

Results of Phase 2 rheumatoid arthritis clinical trial announced

4. September 2009 00:28
Array BioPharma Inc. (Nasdaq: ARRY) today announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients. [More]

Golimumab shows promise for rheumatoid arthritis

28. June 2009 21:37
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet. [More]

Posted in: Drug Trial News

Tags: , , , , ,

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

1. June 2009 19:33
Biologic disease-modifying antirheumatic drugs (DMARDs) such as adalimumab, etanercept and infliximab are effective at reducing symptoms and slowing progression of rheumatoid arthritis (RA). These drugs act more quickly, require less laboratory monitoring, and are better tolerated than nonbiologic DMARDs, but they are also up to 100 times more expensive. [More]

Posted in: Pharmaceutical News

Tags: , , , , , ,

Mice with "superhealing" powers provide clues to treating arthritis caused by traumatic injury

22. February 2009 22:31
A strain of laboratory mice that has "superhealing" powers has been found to resist inflammation after a knee injury, and also to avoid developing arthritis at the injury site in the long term, according to researchers at Duke University Medical Center. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.